Addex gabab pam candidate demonstrates robust anti-tussive activity in multiple chronic cough preclinical models

Ad hoc announcement pursuant to art. 53 lr  geneva, switzerland, june 6, 2025 - addex therapeutics (six: adxn and nasdaq: adxn), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today robust anti-tussive activity of its novel gamma-aminobutyric acid sub-type b receptor (gabab) positive allosteric modulator (pam) in multiple preclinical models of chronic cough compared to reference drugs.
ADXN Ratings Summary
ADXN Quant Ranking